These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 14760509)

  • 1. Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer.
    Cohen SJ; Gallo J; Lewis NL; Alpaugh RK; Gentner L; Rogatko A; Yeslow G; Schol J; Verhaeghe T; Zannikos P; Palmer PA; Weiner LM; Meropol NJ
    Cancer Chemother Pharmacol; 2004 Jun; 53(6):513-8. PubMed ID: 14760509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer.
    Zujewski J; Horak ID; Bol CJ; Woestenborghs R; Bowden C; End DW; Piotrovsky VK; Chiao J; Belly RT; Todd A; Kopp WC; Kohler DR; Chow C; Noone M; Hakim FT; Larkin G; Gress RE; Nussenblatt RB; Kremer AB; Cowan KH
    J Clin Oncol; 2000 Feb; 18(4):927-41. PubMed ID: 10673536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer.
    Adjei AA; Croghan GA; Erlichman C; Marks RS; Reid JM; Sloan JA; Pitot HC; Alberts SR; Goldberg RM; Hanson LJ; Bruzek LM; Atherton P; Thibault A; Palmer PA; Kaufmann SH
    Clin Cancer Res; 2003 Jul; 9(7):2520-6. PubMed ID: 12855626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I and pharmacokinetic study of irinotecan in combination with R115777, a farnesyl protein transferase inhibitor.
    Sparreboom A; Kehrer DF; Mathijssen RH; Xie R; de Jonge MJ; de Bruijn P; Planting AS; Eskens FA; Verheij C; de Heus G; Klaren A; Zhang S; Verhaeghe T; Palmer PA; Verweij J
    Br J Cancer; 2004 Apr; 90(8):1508-15. PubMed ID: 15083177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma.
    Cohen SJ; Ho L; Ranganathan S; Abbruzzese JL; Alpaugh RK; Beard M; Lewis NL; McLaughlin S; Rogatko A; Perez-Ruixo JJ; Thistle AM; Verhaeghe T; Wang H; Weiner LM; Wright JJ; Hudes GR; Meropol NJ
    J Clin Oncol; 2003 Apr; 21(7):1301-6. PubMed ID: 12663718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors.
    Punt CJ; van Maanen L; Bol CJ; Seifert WF; Wagener DJ
    Anticancer Drugs; 2001 Mar; 12(3):193-7. PubMed ID: 11290865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting.
    Kurzrock R; Kantarjian HM; Cortes JE; Singhania N; Thomas DA; Wilson EF; Wright JJ; Freireich EJ; Talpaz M; Sebti SM
    Blood; 2003 Dec; 102(13):4527-34. PubMed ID: 12947010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial.
    Karp JE; Lancet JE; Kaufmann SH; End DW; Wright JJ; Bol K; Horak I; Tidwell ML; Liesveld J; Kottke TJ; Ange D; Buddharaju L; Gojo I; Highsmith WE; Belly RT; Hohl RJ; Rybak ME; Thibault A; Rosenblatt J
    Blood; 2001 Jun; 97(11):3361-9. PubMed ID: 11369625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma.
    Rosenberg JE; von der Maase H; Seigne JD; Mardiak J; Vaughn DJ; Moore M; Sahasrabudhe D; Palmer PA; Perez-Ruixo JJ; Small EJ
    Cancer; 2005 May; 103(10):2035-41. PubMed ID: 15812833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer.
    Crul M; de Klerk GJ; Swart M; van't Veer LJ; de Jong D; Boerrigter L; Palmer PA; Bol CJ; Tan H; de Gast GC; Beijnen JH; Schellens JH
    J Clin Oncol; 2002 Jun; 20(11):2726-35. PubMed ID: 12039935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors.
    Pitot HC; Adjei AA; Reid JM; Sloan JA; Atherton PJ; Rubin J; Alberts SR; Duncan BA; Denis L; Schaaf LJ; Yin D; Sharma A; McGovren P; Miller LL; Erlichman C
    Cancer Chemother Pharmacol; 2006 Aug; 58(2):165-72. PubMed ID: 16328416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I and pharmacokinetic study of irinotecan in combination with raltitrexed.
    Lewis NL; Scher R; Gallo JM; Engstrom PF; Szarka CE; Litwin S; Adams AL; Kilpatrick D; Brady D; Weiner LM; Meropol NJ
    Cancer Chemother Pharmacol; 2002 Oct; 50(4):257-65. PubMed ID: 12357298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.
    Soepenberg O; Dumez H; Verweij J; de Jong FA; de Jonge MJ; Thomas J; Eskens FA; van Schaik RH; Selleslach J; Ter Steeg J; Lefebvre P; Assadourian S; Sanderink GJ; Sparreboom A; van Oosterom AT
    Clin Cancer Res; 2005 Feb; 11(4):1504-11. PubMed ID: 15746053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancer.
    Lebowitz PF; Eng-Wong J; Widemann BC; Balis FM; Jayaprakash N; Chow C; Clark G; Gantz SB; Venzon D; Zujewski J
    Clin Cancer Res; 2005 Feb; 11(3):1247-52. PubMed ID: 15709195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study.
    Tolcher AW; LoRusso P; Arzt J; Busman TA; Lian G; Rudersdorf NS; Vanderwal CA; Waring JF; Yang J; Holen KD; Rosen LS
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):1041-9. PubMed ID: 26429709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors.
    Jimeno A; Rudek MA; Purcell T; Laheru DA; Messersmith WA; Dancey J; Carducci MA; Baker SD; Hidalgo M; Donehower RC
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):423-33. PubMed ID: 17429623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer.
    Rao S; Cunningham D; de Gramont A; Scheithauer W; Smakal M; Humblet Y; Kourteva G; Iveson T; Andre T; Dostalova J; Illes A; Belly R; Perez-Ruixo JJ; Park YC; Palmer PA
    J Clin Oncol; 2004 Oct; 22(19):3950-7. PubMed ID: 15459217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I and pharmacokinetic study of fixed-dose selenomethionine and irinotecan in solid tumors.
    Fakih MG; Pendyala L; Smith PF; Creaven PJ; Reid ME; Badmaev V; Azrak RG; Prey JD; Lawrence D; Rustum YM
    Clin Cancer Res; 2006 Feb; 12(4):1237-44. PubMed ID: 16489079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/II study of escalating doses of nedaplatin in combination with irinotecan for advanced non-small-cell lung cancer.
    Oshita F; Yamada K; Kato Y; Ikehara M; Noda K; Tanaka G; Nomura I; Suzuki R; Saito H
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):73-8. PubMed ID: 12750839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors.
    Soepenberg O; Dumez H; Verweij J; Semiond D; deJonge MJ; Eskens FA; ter Steeg J; Selleslach J; Assadourian S; Sanderink GJ; Sparreboom A; van Oosterom AT
    J Clin Oncol; 2005 Feb; 23(4):889-98. PubMed ID: 15681535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.